Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy.
PMID: 30906435
2019
Experimental and therapeutic medicine
Result: Common and frequent mutations identified in the cohort of the present study included rtL80V/I, rtV84M, rtL91I, rtN118H/D/T, rtT128A, rtL180M, rtT184L/S/A, rtV191I, rtS202G, rtV207I/M, rtS213T
Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
Method: Recombinant vectors that harboured a patient-derived rtL180M+A181C+M204V, rtL180M+A181C+M204V+S202G, rtL180M+
Result: In addition, the colocalization of rtL180M+A181C+M204V mutations and rtT184A or rtM250V mutation on the same viral genome was verified in the samples of three patients (P1, P2, P10).
[Monitoring by high-sensitivity HBV DNA assay during treatment in chronic hepatitis B e antigen negative patients].
Abstract: New mutation sites such as G1915A / C, L180M, M204V, V207I / L, T184A and V173L were detected, Low resistance rate (25%).
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Method: Also, a recent study using direct sequencing of samples from 131 treatment-naive patients infected with genotype C2 reported an overall rate of 12.98% for primary (rtT184A/C/F and rtM204I/V) or compensatory (rtL80I and rtL180M) mutations.
Table: T184A/C
Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.
Result: By contrast, the other patient experienced a virologic breakthrough harboring the novel substitutions rt
Result: Due to the presence of ETVr substitutions rtT184A/S in this patient, ETV susceptibility was not assessed.
Result: Phenotypic analysis of the remaining 12 of 15 identified novel emergent substitutions indicated a reduced susceptibility to ETV (>758-fold greater than WT; Table 2) due to the presence of high-level ETVr HBV RT substitutions rtT184L, rtT184A, rtS202G, or rtM250V (Table 2).
Table: T184A
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.
Introduction: Virological breakthrough on TDF therapy has been reported in two patients harbouring rtS78T/sC69 mutations, and in another patient with multi-site polymerase mutations; rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and
HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining.
Abstract: Secondary substitutions (rtL80V and rtV173G/A/L) occurred more frequently than primary NUCr substitutions (rtI169L; rtA181G; T184A/S; rtS202T/R; rtM204L and rtM250K).
Introduction: According to several clinical practice guidelines and authoritative reviews, NUCr substitutions can be classified into two categories: primary NUCr substitutions at 8 codons (rtI169T,
Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.
Result: Other substitutions (rtI169T/V, rtV173A/M, rtT184A/I, rtA194 V/T, rtQ215R/H, rt
Result: Other substitutions (rtI169T/V, rtT184A/I, rtA194 V/T, rtV214A, rtM250 V) were present at low levels (<1%).
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).
HBV mutation literature information.
PMID: 
2019
Experimental and therapeutic medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT